ヘルスケア
ヘルスケアは、グローバルトレンド、技術・革新及び各国の市場特性、人口動態や規制当局に影響を受けるセクターです。
アジアにおける投資及び業界再編に影響を与える主な要因は:
- 可処分所得の増加、急速に変化する多様な人口動態;
- 地理的及び生理学的な特性;
- 政府・行政支援による医療システムの発展;
- メディカル及びライフサイエンステクノロジーに精通するイノベーターの出現;
- グローバル投資家のアジア成長市場への活発な参入、アジア企業による旺盛な域内及び海外M&A意欲
BDAのグローバルヘルスケアチームは、アジア各国の事情に即した深い知見・洞察力、グローバルな視点及び豊富な案件実績により各種事業会社、フィナンシャルスポンサー、起業家などのクライアントに対してフィナンシャルアドバイザリーサービスを提供しています。これまで、ヘルスケアサービス、医療技術、製薬、バイオテクノロジー、外部委託製薬サービス(CRO・CDMO)、コンシューマーヘルス、農動植物ライフサイエンスに対するフィナンシャルアドバイザリー実績を有しています。

Andrew Huntley
Managing Partner, Head of Healthcare
has divested strategic stake to
2025
divested majority stake in
to
2024
acquired majority stake in
2024
has been acquired by
2023
received investment from
2023
a subsidiary of
has acquired
2022
a portfolio company of
has been acquired by
2022
agreed to divest East Syracuse, New York facility to
2022
has sold minority stake to
2022
a portfolio company of
has been acquired by
2022
investment from
2021
has been acquired by
2021
a portfolio company of
has been acquired majority stake by
2021
a portfolio company of
has been acquired by
2021
divested majority stake to
DCP Capital
2021
agreed to divest Couvet, Switzerland facility to WuXi AppTec
2021
raised Series B round from
2021
backed by
has been acquired by
2020
divested Escientia Life Sciences to Deccan Fine Chemicals
2020
divested significant stake in
Kehua Bio-Engineering to Gree Real Estate
2020
majority sale
2019
LAP Lasers a portfolio company of
has been acquired by
2019
divested majority stake to
2019
a portfolio company of
has been acquired by
AGIC and Humanwell
2017
recapitalized majority by
2017
divested CMC Biologics to
2017
has been acquired by a Japanese chemicals & life science company
2016
acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013
divested Radiant Research Inc, US-based clinical research company
2012
divested medical supply business to
2012